GlaxoSmithKline LLC, et al. v. Glenmark Pharmaceuticals Inc., USA, et al., C.A. Nos. 14-877-LPS-CJB; 14-878-LPS-CJB, June 3, 2016.
Burke, M. J. Report and Recommendation regarding claim construction issues regarding six terms from one patent. A Markman hearing took place on April 4, 2016.
The disputed technology relates to a beta blocking pharmaceutical. The following terms were considered:
-
“decreasing mortality caused by congestive heart failure" I "to decrease a risk of mortality caused by congestive heart failure"
-
“maintenance period”
-
“maintenance dosages”
-
"administering"
-
"have been shown to statistically decrease"
-
"congestive heart failure"